Medical device company Sygnis has unveiled its TruePrime Single Cell WGA Kit V2 for whole genome amplification (WGA) from a broader range of cell type for an extended application.
The device is based on Sygnis’ patented TruePrime technology and is independent of the requirement of random synthetic primers.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The DNA amplification technology features a combination of proteins which works together to amplify the smallest amounts of DNA.
Sygnis CEO and CFO Pilar de la Huerta said: “Our newly launched TruePrime Single Cell WGA V2 Kit, once again, proves our innovation strength and our commitment to develop products with superior features addressing urgent needs in molecular biology, especially in areas such as next generation sequencing and single cell analysis.
“We make good progress in establishing ourselves as a global leader in the development and commercialisation of innovative tools for processing genetic information for a multitude of applications in fast growing markets such as human genetics, oncology, molecular diagnostics and personalised medicine.”
The easy to use TruePrime Single Cell WGA V2 Kit operates sensitively and works with all commonly used next generation sequencing (NGS) platforms such as Illumina and IonTorrent.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe kit also promotes new lysis conditions enabling WGA from a broader range of cell types and at the same time increase the number of applications.
Lysis is considered important particularly in single cell analysis because of the limited sample volumes.
The kit includes human genomic DNA as an internal positive control encompassing the overall amplification process.
